Overview

• A Vanderbilt cohort analysis of 33,822 veterans, published in JAMA Dermatology, linked oral nicotinamide use to reduced incidence of new skin cancers.
• Overall risk fell 14% among users compared with nonusers in the health records review.
• Starting the supplement after a first diagnosis was associated with reductions approaching 50% and up to 54%.
• The greatest impact was reported for squamous cell carcinoma with declines over 20%, with signals seen after as little as 30 days of use at 500 mg twice daily.
• Researchers describe the evidence as observational and encourage prospective trials, framing nicotinamide as an accessible adjunct to sun-protection rather than a replacement.